Time-related differences in the physical property profiles of oral drugs

被引:235
作者
Leeson, PD
Davis, AM
机构
[1] AstraZeneca R&D Charnwood, Dept Med Chem, Loughborough LE11 5RH, Leics, England
[2] AstraZeneca R&D Charnwood, Dept Phys & Metab Sci, Loughborough LE11 5RH, Leics, England
关键词
D O I
10.1021/jm049717d
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Comparisons of the calculated physicochemical properties of oral drugs launched prior to 1983 (864 drugs) and between 1983 and 2002 (329 drugs) show that mean values of lipophilicity, percent polar surface area and H-bond donor count are the same, suggesting that these are the most important oral druglike physical properties. In contrast, mean values of molecular weight and the numbers of O + N atoms, H-bond acceptors, and rotatable bonds and rings have increased in 1983-2002 drugs (by 13-29%). Analysis of the 1983-2002 oral drugs by therapy area shows that antiinfectives and nervous system drugs have the most extreme physical property profiles. Cardiovascular drugs show increasing molecular weight with year of publication, primarily a consequence of focusing on clinically proven mechanisms, with limited chemical diversity. Drug classes other than antiinfectives show comparable distributions of lipophilicity, suggesting that this property in oral drugs is important irrespective of the drug's target. The results suggest that the balance between polar and nonpolar drug properties is an important, unchanging feature of oral drug molecules.
引用
收藏
页码:6338 / 6348
页数:11
相关论文
共 44 条
[1]   HYDROGEN-BONDING .32. AN ANALYSIS OF WATER-OCTANOL AND WATER-ALKANE PARTITIONING AND THE DELTA-LOG-P PARAMETER OF SEILER [J].
ABRAHAM, MH ;
CHADHA, HS ;
WHITING, GS ;
MITCHELL, RC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (08) :1085-1100
[2]  
Abraham MH, 1999, PESTIC SCI, V55, P78, DOI 10.1002/(SICI)1096-9063(199901)55:1<78::AID-PS853>3.0.CO
[3]  
2-7
[4]  
Blake JF, 2003, BIOTECHNIQUES, P16
[5]   Predicting drug absorption: How nature made it a difficult problem [J].
Burton, PS ;
Goodwin, JT ;
Vidmar, TJ ;
Amore, BM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :889-895
[6]  
Chan OH, 1996, DRUG DISCOV TODAY, V1, P461
[8]   Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs [J].
Doan, KMM ;
Humphreys, JE ;
Webster, LO ;
Wring, SA ;
Shampine, LJ ;
Serabjit-Singh, CJ ;
Adkison, KK ;
Polli, JW .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :1029-1037
[9]  
DOHERTY A, 2003, ANNU REP MED CHEM, V38, P425
[10]  
Egan WJ, 2002, CURR OPIN DRUG DISC, V5, P540